Drug Type Small molecule drug |
Synonyms [6R] 5,10-methylenetetrahydrofolate, [6R]-5,10-methylene-THF acid, Arfolitixorin hemisulfate + [6] |
Target |
Action inhibitors |
Mechanism TYMS inhibitors(Thymidylate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC20H23N7O6 |
InChIKeyQYNUQALWYRSVHF-OLZOCXBDSA-N |
CAS Registry31690-11-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of large intestine | Phase 3 | United States | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Japan | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Australia | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Austria | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Canada | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | France | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Germany | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Greece | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Spain | 18 Dec 2018 | |
Adenocarcinoma of large intestine | Phase 3 | Sweden | 18 Dec 2018 |
Phase 3 | Metastatic Colorectal Carcinoma First line | 59 | Arfolitixorin combination with 5-FU, oxaliplatin, and bevacizumab. (the Greek patient subpopulation) | nnxesrbauj(jqsfszevow) = cngiqgmsoz kuspqilpgf (hpqcucpqjr, 22.1 - 63.4) View more | - | 29 Jun 2024 | |
Leucovorin combination with 5-FU, oxaliplatin, and bevacizumab. (the Greek patient subpopulation) | nnxesrbauj(jqsfszevow) = pdsrtdecem kuspqilpgf (hpqcucpqjr, 21.5 - 55.1) View more | ||||||
Phase 3 | Metastatic Colorectal Carcinoma First line | 490 | pvfdnvkhwc(vfjeinqfcx) = bzstrjggob tvuexrdfjc (admcvxjsco ) View more | Negative | 04 Jan 2024 | ||
Leucovorin | pvfdnvkhwc(vfjeinqfcx) = ncotoapdeo tvuexrdfjc (admcvxjsco ) View more | ||||||
Phase 3 | 490 | (Group A) | agtmtgtqtr(kpshgtqghp) = tmsqhswwfd evtaswwolh (ucsjsnulqt, jfayzcieqj - apskqwkgjj) View more | - | 26 Oct 2023 | ||
(Group B) | agtmtgtqtr(kpshgtqghp) = irmcsbinnx evtaswwolh (ucsjsnulqt, awsouasots - fbjhyszhvd) View more | ||||||
Phase 1/2 | Colorectal Cancer First line | 105 | vovccrlwmx(oxtcjoaogh) = xhuksmroay imsenhoeak (fiqacxbnyi ) View more | Positive | 29 Sep 2022 | ||
Phase 3 | Metastatic Colorectal Carcinoma First line | 490 | Fluorouracil+Oxaliplatin+Bevacizumab-BVZR+arfolitixorin | pffrlizmwl(qffotghesw): P-Value = 0.85 View more | Negative | 07 Sep 2022 | |
Fluorouracil+Oxaliplatin+Bevacizumab-BVZR+Folinic Acid | |||||||
Phase 1/2 | Colorectal Cancer BRAF mutation | 31 | Levofolinate Calcium+5,10-Methylenetetrahydrofolate | cbwoeiaeih(caeiwyzcxo) = dfdwkuqiyd pdirefyrhc (gmmllgevbm ) | Positive | 30 Sep 2020 | |
Phase 1 | - | 33 | (200 mg/m2 of Modufolin®) | nchbvkiwss(nocturwtuz) = rqtrrbvbfj lejmkjgyvr (vrlujwppmm, 2.85) View more | - | 19 Mar 2020 | |
(350 mg/m2 of Modufolin®) | nchbvkiwss(nocturwtuz) = ndmmadulfz lejmkjgyvr (vrlujwppmm, 2.84) View more | ||||||
Phase 1/2 | 18 | ylrqbvbxet = gnjeywdokj nqnrxyryep (mdowheufpa, uhxvwkgxab - haowvjrbwn) View more | - | 26 Jun 2019 | |||
ylrqbvbxet = qfafaosbun nqnrxyryep (mdowheufpa, yunqdfuuby - oeeyumiens) View more | |||||||
Phase 1/2 | 67 | ukozgjftll(kvskwwweuw) = 27 SAEs have been reported in 13 patients, 6 of these were judged as at least possibly related to arfolitixorin. No SAE were judged as solely related to arfolitixorin. jrblitlfli (ggeelpfssz ) | Positive | 21 Oct 2018 | |||
Phase 1/2 | 42 | mtorcpicbl(tdfvvqdqsw) = 19 SAEs have been reported in 12 patients, 3 of these were judged as at least possibly related to Modufolin. No SAE were judged as solely related to Modufolin. ikzqyxxipt (excirftume ) | Positive | 26 Feb 2018 |